Fujian Cosunter Pharmaceutical (300436) Fundamentals 2026 — Revenue Analysis | SniperIQ
Fujian Cosunter Pharmaceutical (300436) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥14.6B, trading at ¥91.36 on the SHZ. This SniperIQ fundamentals page covers Fujian Cosunter Pharmaceutical's valuation, profitability (net margin -51.9%), revenue (¥416M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fujian Cosunter Pharmaceutical's market cap?
Fujian Cosunter Pharmaceutical (300436) has a market capitalization of approximately ¥14.6B, trading at ¥91.36 on the SHZ. Market cap moves with the live share price.
What is Fujian Cosunter Pharmaceutical's P/E ratio?
Fujian Cosunter Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 57.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fujian Cosunter Pharmaceutical?
Fujian Cosunter Pharmaceutical runs a net profit margin of -51.9%, a gross margin of 60.9%, and an operating margin of -25.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fujian Cosunter Pharmaceutical generate?
Fujian Cosunter Pharmaceutical reported revenue of ¥416M for fiscal year 2025, with net income of -¥218M and earnings per share (EPS) of -1.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fujian Cosunter Pharmaceutical pay a dividend?
Fujian Cosunter Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Fujian Cosunter Pharmaceutical financially healthy?
Fujian Cosunter Pharmaceutical carries a debt-to-equity ratio of 1.67x and a current ratio of 1.02x, with a market beta of 1.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fujian Cosunter Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fujian Cosunter Pharmaceutical (300436) the key facts are: market cap ¥14.6B, revenue ¥416M, 52-week range 67.43-188.93. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Fujian Cosunter Pharmaceutical's full fundamentals live
Get Fujian Cosunter Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.